Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43390
UPID:
HNRPR_HUMAN
Alternative names:
-
Alternative UPACC:
O43390; Q2L7G6; Q5TEH1; Q9BV64; S4R3J4
Background:
Heterogeneous nuclear ribonucleoprotein R (hnRNP R) plays a pivotal role in the processing of precursor mRNA in the nucleus, as a component of ribonucleosomes. These complexes, comprising at least 20 different hnRNP proteins, are crucial for the post-transcriptional regulation of gene expression.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by developmental delays, structural brain abnormalities, and skeletal defects. Understanding the role of Heterogeneous nuclear ribonucleoprotein R could open doors to potential therapeutic strategies for this disorder.